Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IQKOR
ADC Name
CON-4619
Synonyms
Aurixim; CON-4619; Rituximab conjugate (BioIntegrator LLC)
   Click to Show/Hide
Organization
BioIntegrator LLC
Drug Status
Phase 1 (Terminated)
Indication
In total 2 Indication(s)
Follicular lymphoma
Phase 1
Clinical Trial
Unspecific non-hodgkin lymphoma
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Rituximab
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD20 (MS4A1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03057418
Phase 1
Open-label study of safety, tolerability, pharmacokinetics and pharmacodynamics of auriim multiple doses in patients with recurrent/refractory -cell, CD20-positive non-hodgkin lymphoma of low tumor grade or with follicular lymphoma.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT03057418  Clinical Status Phase 1
Clinical Description Open-label study of safety, tolerability, pharmacokinetics and pharmacodynamics of auriim multiple doses in patients with recurrent/refractory -cell, CD20-positive non-hodgkin lymphoma of low tumor grade or with follicular lymphoma.
References
Ref 1 Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriim Multiple Doses in Patients With Recurrent/Refractory -cell, CD20-positive Non-Hodgkin Lymphoma of Low Tumor Grade or With Follicular Lymphoma, NCT03057418